ClinicalTrials.gg
CompletedNCT05013060IBS-PlusUpdated Feb 28, 2024

The Efficacy of Sodium Butyrate and Probiotics in Patients With Irritable Bowel Syndrome

An interventional study of Probiotics and microcapsulated sodium butyrate and Maltodextrin in Irritable Bowel Syndrome, sponsored by Nordic Biotic Sp. z o.o.. Completed at 1 site in Poland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Nordic Biotic Sp. z o.o. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Apr 2021, registered Aug 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Irritable Bowel Syndrome with a site in Poland — 6 open to participants now, 6 under way, none of them phase 3. Irritable Bowel Syndrome · Poland.

Enrollment
14th of 24
120 · median 165
Started
2021
with 1 other
No phase
12 of 27
5 open now
Registered
16th of 27
by date
Lead sponsor
2 of 27
Nordic Biotic Sp. z o.o.

Among the 27 studies in Irritable Bowel Syndrome with a site in Poland, this one is the 14th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2021, is one of 12 with no phase, and was the 16th registered.

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

6 of the 27 studies in Irritable Bowel Syndrome with a site in Poland are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Irritable Bowel Syndrome with a site in Poland, or all of them as a file.
02

Study summary

According to current IBS management guidelines, probiotic administration reduces IBS-associated symptoms and improves the quality of life. The purpose of this study is to assess the effects of the combined formulation comprising microencapsulated sodium butyrate and a probiotic mixture of two Lactobacillus strains (L. rhamnosus and L. acidophilus) and three Bifidobacterium strains (B. longum, B. bifidum, and B. lactis) on the incidence and severity of clinical symptoms in patients diagnosed with irritable bowel syndrome (IBS) based on the Rome IV criteria.

Microencapsulated sodium butyrate is a short-chain fatty acid (SCFA) with biological effects on the gastrointestinal mucosa; it constitutes a key source of energy for enterocytes. Butyrate was shown to have a trophic effect on the colon epithelium and to help restore the disrupted structural and functional integrity of the gastrointestinal tract. These unique properties of sodium butyrate result in its beneficial effects on the abdominal symptoms (such as diarrhea, constipation, abdominal pain) in patients with IBS. This study will assess the effects of the mixture of sodium butyrate and multi-strain probiotic on the rate and severity of clinical symptoms in IBS patients, by taking into account their nutritional status and body composition.

Read the detailed description

The study schedule includes five visits:the screening/baseline visit, whose purpose is to qualify patients to be included in the study, the randomization visit (visit 0), at which patients will be given a probiotic/butyric acid or placebo, and three follow-up visits (at weeks 4, 8, and 12 after randomization).

All patients will undergo:

  1. A physical examination - at each visit;
  2. Nutritional status assessment - at visit 0 and at weeks 4 and 12 of treatment;
  3. Anthropometric measurements - at visit 0 and at weeks 4 and 12 of treatment;
  4. Body composition analysis via bioelectrical impedance analysis (BIA) with the use of a Bodystat machine - at visit 0 and at 4 and 12 weeks of treatment;
  5. Laboratory tests (including complete blood count; liver function tests; bilirubin, amylase, creatinine, CRP, and glucose levels; electrolytes; and an SARS-CoV2 antigen cassette test conducted by a doctor) at the screening visit; and cytokines (IL-6 and macrophage inflammatory protein 1β (MIP-1ß)) at visit 0 and at weeks 4 and 12 of treatment;
  6. Disease severity will be rated with the IBS symptom severity score (IBS-SSS) developed by Francis, Morris, and Whorwell, with mild, moderate, and severe cases indicated by scores of \<175, 175-300, and >300, respectively. In addition, the following scales will be used to assess IBS treatment efficacy: IBS-Quality of Life (IBS-QOL), IBS-Global Improvement Scale (IBS-GIS), and IBS - Adequate Relief (IBS-AR).
  7. The number and type of bowel movements will be assessed with the Bristol Stool Formation scale.
03

Conditions studied

  • Irritable Bowel Syndrome

Keywords

  • Probiotics
  • Butyric acid
  • Microencapsulated sodium butyrate
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females aged from 18 to 70 years, inclusive;
  2. Good physical and mental condition assessed based on the patient's history and physical examination;
  3. Laboratory test results (complete blood count, blood chemistry panel) within normal limits or considered not to be by the Investigator; negative SARS-CoV-2 antibody test;
  4. A voluntarily provided written ;
  5. Diagnosis of IBS based on the Rome IV criteria, e.g. recurrent abdominal pain at least one day a week for the last three months, associated with two or more of the following symptoms (these should be present for the last three months, with the onset of symptoms six months before diagnosis):

    • related to defecation
    • associated with a change in stool frequency and/or
    • associated with a change in stool form (appearance)

    Patients with any of the following forms of IBS will be included:

    • IBS-D - more than 25% of BSF type 6 and 7 stools, and less than 25% of type 1 and 2 stools.
    • IBS-C - more than 25% of BSF type 1 and 2 stools, with less than 25% of type 6 and 7 stools.
    • IBS-M - more than 25% of BSF type 6 and 7 stools and also more than 25% of type 1 and 2 stools.
    • at least moderate symptom severity defined as an IBS-SSS score of >175 (5 items, maximum score 500).
  6. The following medications are allowed during this study, provided they have been used at a stable dose and for at least 1 month prior to the study:

    1. pills or intramuscular contraceptives,
    2. hormone replacement therapy (estrogen/progesterone),
    3. L-thyroxine,
    4. antidepressants at low doses (up to 25 mg of amitriptyline, nortriptyline, or selective serotonin reuptake inhibitor per day)
    5. antihypertensives at low doses (diuretics, angiotensin converting enzyme inhibitors angiotensin receptor antagonists).

Exclusion criteria

Exclusion Criteria:

  1. Unclassified IBS;
  2. Cardiovascular disorders: uncontrolled hypertension (blood pressure >170/100 mmHg), cerebrovascular disease;
  3. Respiratory disorders (asthma, [COPD]).
  4. Hepatic impairment (including status post cholecystectomy), renal impairment, and unexplained blood biochemistry abnormalities: serum creatinine levels over twice the , or ALT levels over twice the upper limit of normal.
  5. Gastrointestinal conditions other than IBS, including clinical or endoscopic diagnosis of gastroenteritis.
  6. Endocrine disorders, including diabetes mellitus (fasting blood glucose >11 mmol/L) and elevated TSH levels.
  7. Severe neurological conditions, with psychosis;
  8. ;
  9. Pregnancy or breastfeeding;
  10. to soy;
  11. Lactose intolerance;
  12. The use of gastrointestinal motility stimulants or dietary fiber supplements during the 2 weeks preceding the clinical study;
  13. The use of antithrombotic drugs;
  14. A surgical procedure scheduled during the course of the clinical study;
  15. Current probiotic use and refusal to undergo a 3-month ;
  16. Antibiotic therapy during the 3 months preceding the study;
  17. Antibiotic use during the study;
  18. Being included in another clinical study during the previous 3 months;
  19. History of alcohol or substance;
  20. Inability to strictly adhere to the Investigators' instructions regarding study procedures and protocol requirements.abuse.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    The mixture of probiotics and microcapsulated sodium butyrate

    One billion of the following strains: Bifidobacterium lactis FloraActive 32269, Bifidobacterium longum FloraActive 32946, Bifidobacterium bifidum FloraActive 32043, Lactobacillus rhamnosus FloraActive 19070-2, Lactobacillus acidophilus FloraActive 32418 and 150 mg microcapsulated sodium butyrate, and 64 mg fructooligosaccharides

    Dietary Supplement: Probiotics and microcapsulated sodium butyrate

  • Placebo comparator
    Placebo

    Maltodextrin

    Dietary Supplement: Maltodextrin

Interventions

  • Dietary supplementProbiotics and microcapsulated sodium butyrate

    The patients who give their consent to take part in this study, will receive an oral microencapsulated sodium butyrate and a mixture of probiotics formulation 2 times a day for a period of 12 weeks.

  • Dietary supplementMaltodextrin

    The patients who give their consent to take part in this study will receive an oral maltodextrin as placebo 2 times a day for a period of 12 weeks.

06

What researchers measure

Primary outcomes

  1. Changes in severity of IBS symptoms using IBS Severity Scoring System (IBS-SSS)

    IBS-SSS is a 5-question survey that asks: 1. the severity of abdominal pain, 2. frequency of abdominal pain, 3. severity of abdominal distention, 4.dissatisfaction with bowel habit, and 5. interference with quality of life over the past 10 days. Subjects respond to each question on a 100-point visual analogue scale. Each of the five question generates a maximum score of 100 point, and total scores can range from 0-500 with higher scores indicating severe symptoms.

    Time frame: Severity of symptoms from baseline at 4, 8 and 12 weeks of intervention

  2. Improvement or worsening of IBS global symptoms using Global Improvement Scale (IBS-GIS)

    IBS-Global Improvement Scale asseses IBS symptoms using a patient-defined 7 point Linkert scale ranging from symptoms substantially worse to substantially improved. Patients answer the question "Have you felt any change in the severity of your symptoms over the past 7 days compared to how you felt before the medicine was given? The answers are recorded based on the 7-point scale: 1. = I feel that the symptoms have worsened significantly 2. = I feel that the symptoms have moderately worsened 3. = I feel that the symptoms have slightly worsened 4. = I feel no change 5. = I feel a slight improvement 6. = I feel moderate improvement 7. = I feel significant improvement IBS-GIS score indicates: improvement if is \>4 or worsening if is\<4, no change if is 4.

    Time frame: Improvement/worsening assessed after 4, 8 and 12 weeks of intervention

  3. Changes in an adequate relief

    IBS-Adequate Relief (IBS-AR) is a dichotomous single item that asks participants "Over the past week (7 days) have you had adequate relief of your IBS symptoms? The answer is YES or NO.

    Time frame: Adequate Relief after 4, 8 and 12 weeks of interventions

  4. Changes in Quality of Life

    The IBS-Quality of Life (IBS-QOL) is a 34-item measure assessing the degree to which IBS interferes with patient quality of life. Each item is rated on a 5-point Likert scale, thus yielding a total score that has a theoretical range of 34 to 170, with higher scores indicating worse QOL.

    Time frame: Quality of Life from baseline at 4, 8 and 12 weeks of intervention

Secondary outcomes

  1. Changes in number and type of stools

    Number of stools per day and type of stools assessed before intervention and then 3 times a week. Type of stools assessed using the Bristol Stool Formation Scale. Bristol Scale is designed to classify faeces into seven groups: type 1-2 indicate constipation, type 3-4 are "normal" stools; type 5-7 indicate diarrhea.

    Time frame: From baseline for 12 weeks of intervention in 1 week intervals

  2. Changes in severity of pain

    The severity of pain assessed before intervention and then 3 times a week using a patient-defined 5 point Linkert scale: point 0 - no pain, and 1-4 the severity of pain with higher scores indicating worse pain.

    Time frame: From baseline for 12 weeks of intervention in 1 week intervals

  3. Changes in flatulence/abdominal distension

    The severity of flatulence/abdominal distension assessed before intervention and then 3 times a week using a patient-defined 5 point Linkert scale: point 0 - no flatulence/abdominal distension, and 1-4 the severity of flatulence/abdominal distension with higher scores indicating worse flatulence/abdominal distension.

    Time frame: From baseline for 12 weeks of intervention in 1 week intervals

  4. Changes in Body Mass Index (BMI)

    The effect of intervention on the patient's weight

    Time frame: From baseline at 4 and 12 weeks of intervention

  5. Body composition analysis

    Body composition will be measured via bioelectrical impedance analysis with the use of a Bodystat machine.

    Time frame: From baseline at 4 and 12 weeks of intervention

Other outcomes

  1. Changes in interleukin 6 (IL-6) and macrophage inflammatory protein 1β (MIP-1ß) levels

    IL-6 and MIP-1ß levels will be measured in the sera of patients using commercially available immunoenzymatic tests.

    Time frame: From baseline at 4 and 12 weeks of intervention

07

Study locations

1 site
  • Medical University of Lodz
    Łódź, 90-647, Poland
08

References and documents

Publications

  • Gasiorowska A, Romanowski M, Walecka-Kapica E, Kaczka A, Chojnacki C, Padysz M, Siedlecka M, Bierla JB, Steinert RE, Cukrowska B. Effects of Microencapsulated Sodium Butyrate, Probiotics and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome: A Study Protocol of a Randomized Double-Blind Placebo-Controlled Trial. J Clin Med. 2022 Nov 7;11(21):6587. doi: 10.3390/jcm11216587. PubMed 36362815 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Sep 2023, 29 months.

Of 52 industry-sponsored interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 29 months is above that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2021
First posted
Aug 19, 2021
StartActual
Apr 15, 2021
Primary completionActual
Sep 30, 2023
CompletionActual
Jan 31, 2024
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05013060
Lead sponsor
Nordic Biotic Sp. z o.o.
Responsible party
Anita Gąsiorowska (MD, PhD, Nordic Biotic Sp. z o.o.) — Principal investigator
First posted
Aug 19, 2021
Start date
Apr 15, 2021
Primary completion
Sep 30, 2023
Completion
Jan 31, 2024
Last update
Feb 28, 2024

Study contacts

Anita Gąsiorowska, MD, PhD
principal investigator · Medical University of Lodz

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion